natgillin/translations-raw huggingface dataset:
The method of claim 3 wherein said skin disorder is skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization. 
Spoj za uporabu prema zahtjevu 6, naznačen time da je navedena kožna bolest senzibilizacija kože, iritacija kože, kožni osip, kontaktni dermatitis ili alergijska kontaktna senzibilizacija kože.
The polypeptide according to claim 2 as set forth in a sequence selected from the group consisting of SEQ ID NO:84, SEQ ID NO:86 and SEQ ID NO:88. 
Polipeptid sukladno Zahtjevu 1 kako je naznačeno u sekvenci odabranoj iz grupe koja sadrži SEQ ID BR:84, SEQ
The apparatus according to claim 1, wherein the predefined volume is from about 1 to about 20 ml. 
Uređaj sukladno Zahtjevu 4 pri čemu je navedeni predefinirani volumen 1 do 20 ml.
a temperature sensor for monitoring the operating temperature of the oxidation catalyst, wherein the temperature sensor is connected to the controller which modulates the input of air to modulate the operating temperature of the oxidation catalyst, 
- < osjetnik temperature za praćenje radne temperature katalizatora, naznačen time da je taj osjetnik temperature spojen na ulaz za dovod zraka tako da se dovod zraka može kontrolirati da bi se podešavala radna temperatura katalizatora,
A fixture block 33 fitted with a hole 34 is also provided, preferably in a lower position transversally along one of the bars, in order to allow the insert to be fixed into place using suitable means (screws, pins or similar), once it has been inserted inside the rifle stock. 
Također je predviđen jedan blok za fiksiranje 33 koji je snabdjeven s rupom 34, poželjno je da je u donjem položaju popreko duž jedne od traka, s namjerom da omogući da se umetak fiksira na svojem mjestu koristeći prikladna sredstva (vijke, klinove ili slično) kada se jednom umetak stavi u kundak puške.
The method as recited in claim 2, wherein said muscular dystrophy is Duchenne muscular dystrophy. 
Spoj za uporabu u skladu s patentnim zahtjevom 4, pri čemu je navedena mišićna distrofija Duchenne mišićna distrofija.
q is an integer from 1 to 5; 
q je cijeli broj od 1 do 5;
A process for preparing a compound of formula (I), as defined in claim 9, comprising the steps of preparing the compound of formula (III), as defined in claim 1, according to the process defined in claims 1, 2 or 3; ii) preparing the compound of formula (II), as defined in claim 4, according to any one of the processes defined in claims 4 to 8, preferably according to the process defined in claim 7; and 
Postupak za proizvodnju spoja formule (I), prema zahtjevu 9, naznačen time, da obuhvaća sljedeće korake: proizvodnja spoja formule (II) prema zahtjevu 4, prema bilo kojem postupku definiranom u zahtjevima 4 do $, poželjno prema postupku definiranom u zahtjevu 7; i dobivanje spoja formule (I), prema bilo kojem postupku definiranom u zahtjevima 9 do 12, poželjno prema postupku definiranom u zahtjevu 11.
and R8 are independently selected from hydrogen, C1-6alkyl, and C3-6cycloalkyl, wherein each of said groups R7 and R8 are in turn optionally substituted with one to two of OH, O(C1-4alkyl), imidazolyl, pyridyl, phenyl, tetrahydrofuryl, NH2, NH(C1-4alkyl), N(C1-4alkyl)2, and N-morpholinyl, or alternatively, R7 and R8 are taken together with the nitrogen atom to which they are attached to form a morpholinyl, piperidinyl, or piperazinyl ring; and/or pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof. 
i R8 su svaki nezavisno jedan od drugog izabrani između vodika, C1-6alkil i C3-6cikloalkil, pri čemu je svaka od skupina R7 i R8 redom po izboru supstituirana jednim do dva OH, O(C1-4alkil), imidazolil, piridil, fenil, tetrahidrofuril, NH2, NH(C1-4alkil), N(C1-4alkil)2 i N-morfolinil, ili alternativno, R7 i R8 zajedno s atomom dušika na koji su spojeni tvore morfolinil, piperidinil ili piperazinil prsten.
cleaning the flax seeds obtained by step (ii) for mucilage by washing 
(iii) ispiranje sjemenki lana dobivenih na ovaj način uklanjanja sluzi;
The method of any one of claims 2 to 4, wherein the patient has an autoimmune or inflammatory disease. 
Metoda 1z bilo kojeg od patentnih zahtjeva 2 do 4, pri čemu pacijent ima autoimunosnu ili upalnu bolest.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
determining whether said level is above or below a value of 6.5 µg/ml, wherein a value below 6.5 µg/ml is indicative of the prognosis of Alzheimer's disease. 
određivanje da li je navedena razina iznad ili ispod vrijednosti od 6.5 ug/ml, pri čemu je vrijednost ispod 6.5 ug/ml indikativna za prognozu Alzheimerove bolesti.
M+ is selected from the group consisting of Li+, Na+, and K+; and/ or 
(€) M je izabran iz grupe koju čine Li", Na" IK"; i/ili
A method of identifying compounds suitable for active immunization of a patient predicted to develop Alzheimer's Disease comprising the steps of: 
Metoda identifikacije spojeva podobnih za aktivnu imunizaciju pacijenta za kojeg se očekuje da razvije
at least one substance which irritates the nasal passages and/or pharynx, 
(a) barem jednu tvar koja nadražuje nosnu šupljinu i/ili šupljinu ždrijela,
Composition comprising at least one peptide or polypeptide comprising the amino acid sequence (X1) nX2X3X4X5GX6P (X7)m (Formula I), wherein 
Sastav, naznačen time, da obuhvaća najmanje jedan peptid ili polipeptid koji sadrži sljedeću aminokiselinsku sekvencu [image] gdje
The composition of any one of claims 1-3, wherein the gelling agent is selected from the group consisting of methyl cellulose, ethyl cellulose, hydroxycellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and mixtures thereof. 
sredstvo za geliranje, pri čemu je sredstvo za geliranje izabrano iz skupine koja se sastoji od karboksivinilnih polimera, metil celuloze, etil celuloze, hidroksiceluloze, hidroksietil celuloze i hidroksipropil celuloze; niži alkil alkohol; vodu;
an amount of the solid form of claim 1 in the range of about 5 wt % to about 50 wt % by the total weight of the composition; 
količinu Spoja I-1 u rasponu od 5 tež.% do 50 tež.% ukupne težine pripravka;
The engaging means further comprises a plurality of half-circles 59 that encircles the CD or DVD. 
Sredstvo za zahvaćanje nadalje sadržava i veći broj polukružnih elemenata 59 koji okružuju CD ili DVD.
A method of protecting natural substances of plant and/or animal origin, which have been taken from the natural life cycle, and/or their processed forms, against attack of fungi, which comprises applying to said natural substances of plant and/or animal origin or their processed forms a combination of components A) and B) according to claim 1 in a synergistically effective amount. 
Postupak za zaštitu prirodnih tvari biljnog i/ili životinjskog porijekla koje su preuzete iz prirodnog životnog ciklusa ifili njihovih obrađenih oblika, od napada gljivica, naznačen time, da sadrži primjenu na navedene prirodne tvari biljnog i/ili životinjskog porijekla ili na njihove obrađene oblike, kombinacije komponenti A) i B) prema zahtjevu 1 u sinergistički učinkovitoj količini.
Ulipristal acetate, or any metabolite thereof, for use in treating or preventing a tumour derived from leiomyomata according to anyone of claims 1 to 9 wherein it is to be administered in form of an oral dosage during a period of about 2 to about 4 months. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku oralne doze kroz period od oko 2 do oko 4 mjeseca.
Consequently, the bottom has to be shaped and/or reinforced in a manner that inhibits optimal collapsing of the bottom part of the bottle, and thus allowing the formation cut-off pockets in the collapsed bottle, where residual beverage can be trapped. 
Zbog toga se dno mora oblikovati i/ili ojačati na način koji sprečava optimalno sklapanje donjeg dijela boce i da se time omogući stvaranje odvojenih džepova u sklopljenoj boci, gdje se može uhvatiti zaostalo piće.
The process according to claim 1 wherein said compound of formula III is present at 5 moles per mole of the compound of formula (II). 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što navedeni spoj formule III dolazi u količini od 5 mol/mol spoja formule II.
A method of treating an HIV infection in a human having or at risk of having an HIV infection by administering to the human a therapeutically effective amount of a pharmaceutical composition comprising a compound of claim 1, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Spoj prema zahtjevu 1 naznačen time da je: Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1-12, ili njegov stereoizomer ili farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač, sredstvo za raspadanje ili pomoćno sredstvo.
The solvent was evaporated and the residue purified by column chromatography on silica gel (eluent: methylene chloride/methanol (90/10)). 
Otapalo se evaporira 1 ostatak pročisti kromatografijom na koloni na silika gelu (eluent: metilen klorid/metanol (90/10)).
The mucosal bioadhesive slow release carrier according to claim 11, wherein said acyclovir is present in an amount from 10 to 500 mg in said carrier. 
Nosač bioadhezivan za sluznicu sa sporim oslobađanjem prema patentnom zahtjevu 11, naznačen time što je navedeni aciklovir prisutan u količini od 10 do 500 mg u navedenom nosaču.
The mixture was shaken under H2 at 55 psi for 4 h., filtered over celite and concentrated. 
Smjesa je mućkana pod H> na 55 psi 4 sata, filtrirana preko celita i koncentrirana.
A compound as defined in any one of claims 1-8 or a pharmaceutically acceptable salt thereof, or a composition according to claim 9 for use in a method of treating multiple sclerosis by administering to a subject in need thereof a therapeutically effective amount. The compound, pharmaceutically acceptable salt, or composition for use according to claim 10, wherein the neurological disease is relapsing-remitting multiple sclerosis. 
(1i) farmaceutski prihvatljivu podlogu. Spoj Formule (III), njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1-11, ili pripravak u skladu s patentnim zahtjevom 12, naznačeni time što su namijenjem upotrebi u liječenju neurološke bolesti. Spoj ili pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 13, naznačeni time što je neurološka bolest multipla skleroza.
The use according to claim 2 wherein the enriched conglutin-Y protein extract or the conglutin-Y protein is comprised in a composition comprising an effective amount of said enriched conglutin-Y protein extract or of said conglutin-Y protein and proper additives and/or diluents in the form of a diet supplement. 
4. Primjena prema zahtjevu 2, naznačena time, da se primjenjuje obogaćeni ekstrakt konglutin-y-proteina ili konglutin-h-proteina obuhvaćen u sastavu, u obliku dodatka prehrani, koji sadrži djelotvornu količinu obogaćenog ekstrakta konglutin-y-proteina ili konglutin-y-proteina i primjerene dodatke i/ili sredstva za razrjeđivanje.
closing and sealing the open mouth of the box. 
- < zatvaranje i brtvljenje gornjeg otvora kutije.
and G have the same meaning as in formula I, and when L1 is nitro, the nitro group is reduced to an amino group and the amino derivative obtained is reacted with a compound of formula III G-A4b-L0 (III), wherein 
A4 1 G imaju isto značenje kao u formuli [; i kada je LI nitro, nitro skupinu se reducira u amino skupinu, a dobiveni amino derivat reagira sa spojem formule III G-A4b-L0 (III), gdje
The method according to claim 2, characterised by regulating the pressure within the boiler during shut down or before shut down. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se tlak regulira u parnom kotlu tijekom gašenja ili prije gašenja.
The compound of claim 28 wherein G2 is methyl. 
Spoj iz zahtjeva 28 gdje je G2 metil.
Isolated nucleic acid encoding an anti-beta7 antibody according to any one of the preceding claims. 
Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća:
In various embodiments, the spacer comprises the amino acid sequence GAP (SEQ ID NO: 9), GPS (SEQ ID NO: 10), or GGS (SEQ ID NO: 11). 
Ciljani terapeutski fuzijski protein prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da razmaknica sadrži sekvencu aminokiseline Gly-Ala-Pro (GAP) (SEQ ID NO: 9) ili Gly-Pro-Ser (GPS) (SEQ ID NO: 10).
An identical incision is placed in the middle of the upper extrusion ridge 11 . 
Jednak zasjek nalazi se u sredini gornjeg udubljenog ruba 11.
A pharmaceutical composition according to any of claims 1 to 34 for use in a method for treating a patient suffering from an inflammatory or obstructive pulmonary disease or condition. 
Ko-suspenzija u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačena time što je namijenjena upotrebi u liječenje pacijenta koji boluje od upalne ili opstruktivne plućne bolesti ili stanja.
delivery of the certificate (4) to the transmitting user (1) through the mail server (14). 
- < dostavu elektronske potvrde (4) korisniku pošiljatelju (1) iz jedinice za obradu (11).
is C1-C6 alkyl or C1-C6 hydroxyalkyl, C1-C3 alkoxyalkyl, amino(C1-C6)alkyl, where the amino group is optionally substituted with one or two C1-C3 alkyl groups, being said alkyl groups linear or branched; C6-C14 aryl or C6-C14 aryl(C1-C6)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group constituted by halogen, hydroxy, C1-C6 alkoxy linear or branched saturated or unsaturated, amino, mono- or di-substituted with C1-C6 alkyl linear or branched; 
R"" je Cr-Cs alkil ili C,-Cg hidroksialkil, C;-C3 alkoksialkil, amino(C;-Cs)alkil, gdje je amino skupina izborno supstituirana s jednom ili dvije C;-C3 alkilne skupine, gdje su navedene alkilne skupine nerazgranate ili razgranate; Cg-Cu arilili C4-Cui4 ariK(Ci-Cs)alkil, gdje je arilna skupina izborno supstituirana s jednim ili više supstituenata, bilo istih ili različitih, koje se bira iz skupine koju čine halogen, hidroksi, nerazgranati ili razgranati zasićeni ili nezasićeni C,-Cg alkoksi, amino, mono- ili disupstituiran s C,-CÂ« alkil nerazgranati ili razgranati; njegovi optički aktivni oblici, poput enantiomera, dijastereomera i njegovih racemičnih oblika, te njegove farmaceutski prihvatljive soli; uz uvjet da R", R* i R* nisu svi istodobno H.
a deletion of one or more amino acids of the pep27 domain; and 
(li) deleciju jedne ili više aminokiselina u domeni pep27; i
The only adequate and widely used model available for purposes of preclinical investigations of multiple sclerosis is the experimental autoimmune encephalomyelitis (EAE) (Mokhatarian et al., Nature 309, 356-358. 
Jedini adekvatan i na široko korišten model, namijenjen za upotrebu kod prekliničkih ispitivanja multiple skleroze, je eksperimentalni autoimuni encefalomijelitis (EAE) (Mokhatarian et al., Nature 309, 356-358.
After stirring for 48 hours, the reaction was filtered, concentrated in vacuo, and purified by reverse phase HPLC to give the title compound. 
Nakon miješanja tijekom 48 sati, reakcijska smjesa se filtrira, koncentrira in vacuo i pročisti obrnuto faznom HPLC da bi se dobio naslovni spoj.
Apparatus for the fermentative production of a biological active compound, characterized in that said apparatus is comprised by at least a first insulator containing a fermenter and is surrounded by a working chamber, wherein said working chamber is connected to the environment via a pressure sluice, wherein a low pressure prevails in the insulator and in the working chamber, wherein the pressure (in relation to ambient pressure) in the insulator is lower than the pressure (in relation to ambient pressure) in the working chamber, and wherein an over pressure prevails in the pressure sluice in relation to ambient pressure. 
L ho ll. Uređaj za fermentativnu proizvodnju biološki aktivnog spoja, naznačen time da se spomenuti uređaj sastoji od barem jednog izolatora koji sadrži fermentor i da je okružen radnom komorom, pri čemu je spomenuta radna komora sa okolinom povezana putem prolaza za tlak, pri čemu u izolatoru i radnoj komori prevladava niski tlak, a tlak u izolatoru je (u odnosu prema atmosferskom uaku) niži od tlaka u radnoj komori (u odnosu prema atmosferskom tlaku) i pri čemu u prolazu za tlak prevladava nadtlak u odnosu prema atmosferskom tlaku.
The process according to any one of preceding claims, wherein said alkyl haloacetate is selected from the group consisting of alkyl bromoacetate, alkyl chloroacetate, and alkyl iodoacetate. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je spomenuti alkil haloacetat izabran iz skupine koja se sastoji od alkil bromacetata, alkil kloracetata, 1 alkil jodacetata.
The antibody of claim 4, wherein at least about 20% to about 100% of the N-linked oligosaccharides in the Fc region are bisected. 
Protutijelo u skladu s patentnim zahtjevom 7, naznačeno time, da su najmanje 20% do 100% N-vezanih oligosaharida u Fc regiji prepolovljeni.
A method for preparing a sulphoxide compound of formula (I) either as a single enantiomer or in an enantiomerically enriched form: wherein: 
Postupak za dobivanje sulfoksidnog spoja sa formulom (I) bilo kao jednostrukog enantiomera ili u enantiomerno obogaćenom obliku:
The reaction mixture was concentrated in vacuo and azeotroped with toluene (3X). 
Reakcijska smjesa se koncentrira in vacuo i azotira toluenom (3x).
purifying the enzyme solution obtained by crude purification, with anion-exchange chromatography; 
purifikaciju enzimske otopine dobivene grubom purifikacijom, sa anionski izmjenjivom kromatografijom;
BMD in the hip increased less than that of the spine, but BMD was elevated at Day 56 in patients administered 3 mg/kg, 5 mg/kg, and 10 mg/kg. 
š Antitijelo za uporabu prema zahtjevu 1, naznačeno time, da je količina Anti-sklerostin antitijela koja se primjenjuje od 1 mg/kg do 3 mg/kg.
The method of claim 42, wherein a viscosity of said synthetic substance reaches a value which tends to infinity over a time interval ranging from 5 seconds to 80 seconds starting from a beginning of the chemical reaction for expansion. 
Postupak prema jednom ili više prethodnih zahtjeva, naznačen time, da viskozitet spomenute sintetičke tvari (4) dostiže vrijednost koja teži u beskonačnost preko vremenskog intervala koji je u rasponu uglavnom od 5 sekundi do 80 sekundi, pokrenutog od početka kemijske reakcije za proširenje.
Usually, the reaction causes the release of H+. 
Obično, reakcija uzrokuje otpuštanje H'.
The motorized buoy of claim 1, wherein the radio control (550) receives control signals for navigating the buoy. 
Motorizirana bova prema zahtjevu 1, naznačena time, da radioupravljač (550) zaprima kontrolne signale za navigaciju bove.
A composition for use in producing skipping of exon 52 in the processing of human dystrophin pre-processed mRNA, comprising a substantially uncharged antisense compound containing 20-35 morpholino subunits linked by phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit, comprising a sequence selected from the group consisting SEQ ID NOS: 372-415, and capable of forming with the complementary mRNA sequence in the dystrophin-gene exon 52, a heteroduplex structure between said compound and mRNA having a Tm of at least 45°C. 
HR P20190387 T1 PATENTNI ZAHTJEVI Protusmisleni oligonukleotid koji sadrži 20-35 morfolino podjedinica povezanih s vezama među podjedinicama koje sadrže fosfor koje spajaju morfolino dušik jedne podjedinice sa 5' 'egzocikličkim ugljikom susjedne podjedinice, koji sadrži baznu sekvencu SEQ ID NO: 382, ili sekvencu koja ima s njom barem 80% identičnosti sekvence, pri čemu su timinske baze proizvoljno uracilne baze, te pri čemu je protusmisleni oligonukleotid komplementaran s ljudskim distrofinom pred-mRNA da se inducira preskakanje eksona 52; ili njegova farmaceutski prihvatljiva sol.
These disadvantages associated with tamoxifen (TAX) are eliminated by tagging it with a triphenylphosphonium via an aliphatic chain (referred to as MitoTAX), where the chain is alkyl or alkenyl, and their corresponding tertiary amine salts, selected from the group of organic salts, such as citrate, acetate, lactate, tartarate, oxalate, ascorbate, mesylate, tosylate or inorganic salts, such as sulphate, halogenide, phosphate and/or their mixtures, alkyl triphenylphosphonium derivatives of tamoxifen have the general formula I, 
HR P20181872 T1 PATENTNI ZAHTJEVI Mitohondrijalni ciljani E i/ili Z izomeri preko alifatskog lanca vezanih trifenil fosfonijskih derivata tamoksifena, gdje je alifatski lanac alkil ili alkenil, i njihove odgovarajuće soli tercijalnog amina, odabrane iz grupe organskih soli, kao što je citrat, acetat, laktat, tartarat, oksalat, askorbat, mesilat, tosilat ili anorganskih soli, kao primjerice sulfat, halogenid, fosfat i/ili njihove mješavine (MitoTAX), alkil trifenil fosfonijski derivati imaju opću formulu I,
In order to verify whether a viscosity-increasing agent is suitable as component (b) for use in the dosage form according to the invention, the active ingredient is mixed with the viscosity-increasing agent and suspended in 10 ml of water at a temperature of 25° C. If this results in the formation of a gel which fulfils the above-stated conditions, the corresponding viscosity-increasing agent is suitable for preventing or averting abuse of the dosage forms according to the invention. 
Radi provjere, da li je sredstvo koje povećava viskozitet, kao komponenta (b), prikladno za primjenu u obliku davanja prema izumu, djelatna tvar se pomiješa sa sredstvom koje povisuje viskozitet i suspendira u 10 ml vode kod temperature od 25C. Ako se pritom stvori gel, koji zadovoljava gore navedene uvjete, odgovarajuće sredstvo za povećanje viskoziteta prikladno je za dodatno predusretanje, odnosno sprečavanje zlouporabe kod oblika davanja prema izumu.
of wherein the aluminum powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between about 4 to 7 microns and the 90th percentile of the particle size distribution has a diameter of less than or equal to about 11.5-15.5 microns. 
Gusta smjesa iz patentnog zahtjeva 1 ili 3, pri čemu aluminij ili prah aluminijeve slitine obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 4 i 7 mikrometara (mikrona) i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 11.5-15.5 mikrometara.
For boats having two engines but no thrusters, the control device could have only switches to control the engines, and the switches for thrusters could be omitted. 
Plovila koja imaju dva motora ali bez potiskivača, upravljački uređaj može sadržavati samo sklopke za upravljanje motorom, a sklopke za potisikivače se mogu izostaviti.
applying the aerated mixture to an agricultural crop. 
(c) nanošenje mješavine sa zrakom na jedan poljoprivredni usjev.
The formulation according to (1) to (3) containing the antibody in an amount of at least 50 mg/ml. 
Formulacija prema zahtjevu 3 naznačena time da sadrži protutijelo u količini od barem 50 mg/ml.
Thus, in a first aspect, the invention provides a series of compounds according to formula I: wherein, R1 is O, or NOR, with R being hydrogen, (C1-6) alkyl or (C1-6) acyl, R2 is methyl or ethyl, and R3 is hydrogen or (C1-15) acyl. 
Prema tome, prvi aspekt ovog izuma je osiguravanje serije spojeva formule I: formula 1 R' gdje R! je 0, ili NOR, gdje R je vodik, (C,.4) alkil ili (C,.6) acil, R? je metil ili etil, a